Event report
Past Event | The Future of Pharma: AI in Drug Research, Quality & Regulatory Affairs
The French Chamber of Commerce in Singapore, together with the Singaporean-German Chamber of Industry and Commerce and Life Science Incubator, co-organised an insightful event at Elementum on “The Future of Pharma: AI in Drug Research, Quality & Regulatory Affairs.”
A distinguished panel of experts shared their perspectives on the practical applications of AI across the drug development lifecycle:
- Damien Keogh, Founder at BluMaiden Biosciences,
- Karin Markgraf, Head of Regulatory Affairs Asia Pacific at Merck Group,
- Maria Aileen Mabunay, Global Medical Lead at Sanofi
Moderated by Maximilian Englisch, Global Vice-President of Sales at WALDNER Group
Key Takeaways:
- Accelerating Drug Discovery with AI
AI is transforming R&D by identifying drug targets faster, predicting clinical trial outcomes, and significantly shortening development timelines. - AI-Driven Regulatory Compliance
From automated document analysis to audit preparation, AI is streamlining regulatory processes while staying aligned with evolving global standards. - Ethical & Effective Data Governance
Successful AI adoption depends on strong data governance — ensuring high-quality data, validated models, and ethical, compliant AI use. - Real-World Impact & Future Outlook
Case studies show how AI is already improving access to medications and patient outcomes, paving the way for a smarter, faster, and more inclusive future in pharma.
Participants gained valuable insights into the future of data governance, ethical AI use and real-world case studies shaping the next generation of personalised medicine.
This event was supported by our Committee Partner, International SOS.
For more information about the Healthcare Committee, please contact Vanessa Hobbs at vhobbs(@)fccsingapore.com.
